Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Living with Atopic Dermatitis poses numerous ... With ongoing advancements in treatment options, there is renewed hope for a smoother, itch-free life and a brighter, healthier future!

Subject to FDA approval, VTAMA cream could become a compelling new treatment option for atopic dermatitis patients, most of whom regard itch as one of the most bothersome symptoms of their disease.” ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Itching is an especially bothersome symptom ... approval from the FDA for the use of VTAMA® in the treatment of atopic dermatitis (including the expected timeframe thereof).

Continuous use of topical ruxolitinib for 8 weeks followed by as-needed use for 44 weeks was effective and well tolerated for the treatment of mild to moderate atopic dermatitis (AD ... point or ...